{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:32:19Z","timestamp":1791199939822,"version":"4.2.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["AMED under Grant Number JP21fk0210090 and JP22fk0210115"],"award-info":[{"award-number":["AMED under Grant Number JP21fk0210090 and JP22fk0210115"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>Pemafibrate is a selective peroxisome proliferator-activated receptor \u03b1 modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease (NAFLD) patients, but efficacy was not clearly elucidated due to the small size of previous study populations. Therefore, we explored pemafibrate efficacy in NAFLD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated pemafibrate efficacy on liver enzymes (<jats:italic>n<\/jats:italic> = 132) and liver shear wave velocity (SWV, <jats:italic>n<\/jats:italic> = 51) in NAFLD patients who had taken pemafibrate for at least 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patient ALT levels were decreased from 81.0 IU\/L at baseline to 48.0 IU\/L at week 24 (<jats:italic>P<\/jats:italic> &amp;lt; 0.0001). Serum levels of aspartate aminotransferase (AST), \u03b3-glutamyl transpeptidase (\u03b3-GTP) and triglyceride (TG) were significantly decreased, and high-density lipoprotein cholesterol and platelet count were significantly increased, with no change in body weight being observed. Study participant SWV values decreased from 1.45 m\/s at baseline to 1.32 m\/s at week 48 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). Older age (<jats:italic>P<\/jats:italic> = 0.035) and serum TG levels (<jats:italic>P<\/jats:italic> = 0.048) were significantly associated with normalized ALT. Changes in AST, ALT, \u03b3-GTP and body weight were significantly correlated with change in SWV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pemafibrate significantly improves liver function, serum TG and liver stiffness in NAFLD patients. Pemafibrate is a promising therapeutic agent for NAFLD and may be a candidate for NAFLD patients with elevated TG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1073025","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:31:57Z","timestamp":1675751517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Ryosuke","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoh","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Shigefuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis.","author":"Farrell","year":"2006","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and nash: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in nafld: a population-based cohort study.","volume":"42","author":"Bjorkstrom","year":"2022","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020.","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/hepr.13688","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020.","volume":"51","author":"Tokushige","year":"2021","journal-title":"Hepatol Res."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMALPHA): the next generation of peroxisome proliferator-activated receptor alpha-agonists.","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J Clin Lipidol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (prominent) study.","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors Nf-Kappab and Ap-1.","volume":"274","author":"Delerive","year":"1999","journal-title":"J Biol Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (spparmalpha), versus placebo in patients with non-alcoholic fatty liver disease.","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a Novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective pparalpha modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020401","article-title":"Effects of a novel selective peroxisome proliferator-activated receptor alpha modulator, pemafibrate, on metabolic parameters: a retrospective longitudinal study.","volume":"10","author":"Yanai","year":"2022","journal-title":"Biomedicines."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122316","article-title":"Pemafibrate ameliorates liver dysfunction and fatty liver in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a retrospective study with the outcome after a mid-term follow-up.","volume":"11","author":"Ikeda","year":"2021","journal-title":"Diagnostics."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-Week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the fibroscan-aspartate aminotransferase score.","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open."},{"key":"B17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5114\/ceh.2021.106864","article-title":"Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.","volume":"7","author":"Shinozaki","year":"2021","journal-title":"Clin Exp Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2169\/internalmedicine.6574-20","article-title":"Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: a retrospective, single-arm study.","volume":"60","author":"Hatanaka","year":"2021","journal-title":"Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5114\/ceh.2020.99528","article-title":"Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.","volume":"6","author":"Shinozaki","year":"2020","journal-title":"Clin Exp Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/hepr.13571","article-title":"Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study.","volume":"50","author":"Seko","year":"2020","journal-title":"Hepatol Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.33160\/yam.2020.08.009","article-title":"Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease.","volume":"63","author":"Ikeda","year":"2020","journal-title":"Yonago Acta Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1478-3231.2009.02130.x","article-title":"Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study.","volume":"30","author":"Takahashi","year":"2010","journal-title":"Liver Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1111\/j.1365-2893.2011.01537.x","article-title":"Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis.","volume":"19","author":"Friedrich-Rust","year":"2012","journal-title":"J Viral Hepat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"Fib-4: an inexpensive and accurate marker of fibrosis in hcv infection. comparison with liver biopsy and fibrotest.","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","article-title":"Liver stiffness diminishes with antiviral response in chronic hepatitis C.","volume":"34","author":"Hezode","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1111\/hepr.12456","article-title":"Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients.","volume":"45","author":"Seko","year":"2015","journal-title":"Hepatol Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","article-title":"Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.","volume":"51","author":"Argo","year":"2009","journal-title":"J Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in nafld after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1148\/radiol.220220","article-title":"Two-dimensional shear-wave elastography and us attenuation imaging for nonalcoholic steatohepatitis diagnosis: a cross-sectional, multicenter study.","volume":"305","author":"Jang","year":"2022","journal-title":"Radiology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cgh.2020.05.034","article-title":"Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis.","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in accord type 2 diabetic participants.","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine.","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron."},{"key":"B35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1124\/jpet.107.129197","article-title":"Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release.","volume":"324","author":"Chen","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030706","article-title":"Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (Spparmalpha), in dyslipidemic patients with renal impairment.","volume":"20","author":"Yokote","year":"2019","journal-title":"Int J Mol Sci."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1073025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:32:00Z","timestamp":1675751520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1073025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":36,"alternative-id":["10.3389\/fmed.2023.1073025"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1073025","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1073025"}}